Organigram Global (NASDAQ:OGI) versus BioLife Solutions (NASDAQ:BLFS) Critical Contrast

Organigram Global (NASDAQ:OGI) and BioLife Solutions (NASDAQ:BLFS) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, dividends, valuation and earnings.

Analyst Recommendations

This is a summary of recent ratings for Organigram Global and BioLife Solutions, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organigram Global	1	0	2	0	2.33
BioLife Solutions	1	0	3	1	2.80

BioLife Solutions has a consensus target price of $32.00, suggesting a potential upside of 50.87%. Given BioLife Solutions’ stronger consensus rating and higher possible upside, analysts plainly believe BioLife Solutions is more favorable than Organigram Global.

Volatility and Risk

Organigram Global has a beta of 1.5, meaning that its share price is 50% more volatile than the S&P 500. Comparatively, BioLife Solutions has a beta of 1.97, meaning that its share price is 97% more volatile than the S&P 500.

Insider & Institutional Ownership

34.6% of Organigram Global shares are held by institutional investors. Comparatively, 93.2% of BioLife Solutions shares are held by institutional investors. 0.1% of Organigram Global shares are held by company insiders. Comparatively, 2.2% of BioLife Solutions shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Organigram Global and BioLife Solutions’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Organigram Global	6.03%	-15.41%	-10.49%
BioLife Solutions	-4.50%	1.71%	1.54%

Earnings and Valuation

This table compares Organigram Global and BioLife Solutions”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organigram Global	$185.07 million	1.08	-$17.70 million	$0.14	10.14
BioLife Solutions	$96.21 million	10.78	-$4.59 million	($0.11)	-192.82

BioLife Solutions has lower revenue, but higher earnings than Organigram Global. BioLife Solutions is trading at a lower price-to-earnings ratio than Organigram Global, indicating that it is currently the more affordable of the two stocks.

Summary

BioLife Solutions beats Organigram Global on 11 of the 15 factors compared between the two stocks.

About Organigram Global

Organigram Holdings Inc., through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co., Edison JOLTS, Tremblant, and Laurentian brands. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative-based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as consumer channels. The company was incorporated in 2010 and is headquartered in Toronto, Canada.

About BioLife Solutions

BioLife Solutions, Inc. develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line that comprises of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides cryogenic freezer technology for controlled rate freezing and cryogenic storage of biologic materials; ultra-low temperature mechanical freezers; evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage and transport services. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.